过去7年,相继发表了9项重要高血压临床试验:高血压的合理治疗(hypertension optimal treatment,HOT)、卡托普利预防试验(captopril prevention project,CAPPP)、瑞典老人高血压试验-2(Swedish trial in old patients with hyperte...过去7年,相继发表了9项重要高血压临床试验:高血压的合理治疗(hypertension optimal treatment,HOT)、卡托普利预防试验(captopril prevention project,CAPPP)、瑞典老人高血压试验-2(Swedish trial in old patients with hypertension 2,STOP-2)、抗高血压药和调血脂药预防心脏病发作试验(antihypertensive and lipid-lowering treatment to prevent heart attack trial,ALLHAT)、北欧地尔硫(艹卓)试验(Nordic diltiazem study,NORDIL)、高血压治疗目标(intervention as a goal in hypertension treatment,INSIGHT)、氯沙坦对高血压试验终点的干预(losartan intervention for endpoint reduction in hypertension study,LIFE)、缬沙坦长期使用评估(valsartan antihypertensive long-term use evaluation,VALUE)、英国人和斯堪的那维亚人心脏试验-降血压篇(Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm,ASCOT-BPLA),使高血压治疗观念和策略发生日新月异变化.可概括为早期、快速、平稳、联合、综合.展开更多
文摘过去7年,相继发表了9项重要高血压临床试验:高血压的合理治疗(hypertension optimal treatment,HOT)、卡托普利预防试验(captopril prevention project,CAPPP)、瑞典老人高血压试验-2(Swedish trial in old patients with hypertension 2,STOP-2)、抗高血压药和调血脂药预防心脏病发作试验(antihypertensive and lipid-lowering treatment to prevent heart attack trial,ALLHAT)、北欧地尔硫(艹卓)试验(Nordic diltiazem study,NORDIL)、高血压治疗目标(intervention as a goal in hypertension treatment,INSIGHT)、氯沙坦对高血压试验终点的干预(losartan intervention for endpoint reduction in hypertension study,LIFE)、缬沙坦长期使用评估(valsartan antihypertensive long-term use evaluation,VALUE)、英国人和斯堪的那维亚人心脏试验-降血压篇(Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm,ASCOT-BPLA),使高血压治疗观念和策略发生日新月异变化.可概括为早期、快速、平稳、联合、综合.